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Abstract
Since November 2009 carbapenemase-producing Klebsiella pneu-
moniae isolates have been detected in increasing numbers at the
Clinical Centre University of Pecs. Molecular typing was per-
formed for 102 clinical isolates originating from different time
periods and various departments of the Clinical Centre. Pulsed--
field gel electrophoresis revealed the predominance of a single
clone (101/102), identified as sequence type ST15. PCR and
sequencing showed the presence of blaCTX-M-15 and blaVIM-4
genes. The blaVIM-4 was located on a class 1 integron designated
In238b. To our knowledge, this is the first description of a
blaVIM-4 gene in the predominant CTX-M-15 extended spectrum
b-lactamase-producing Hungarian Epidemic Clone/ST15.
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Overuse of carbapenems due to the increasing prevalence of
infections caused by third-generation cephalosporin-resistant
Enterobacteriaceae has promoted the emergence of carbape-
nem-resistant isolates. Decreased susceptibility to carbapen-
ems in Enterobacteriaceae can be caused by various mechanisms
including production of carbapenemases (IMP, KPC, NDM,
OXA-48, VIM) or production of extended spectrum b-lactam-
ase (ESBL) or AmpC-type enzymes in conjunction with
mutations of porins [1,2]. In Hungary the first carbapenemase
identified was VIM-4, located on In238b in Pseudomonas
aeruginosa in 2002 [3]. In238b was later found in Aeromonas
hydrophila, Klebsiella pneumoniae sequence type 11 (ST11) and
Klebsiella oxytoca [4,5]. Beside VIM-4, production of KPC-2 by
K. pneumoniae ST258 was reported in Hungary [6]. The first
carbapenemase-producing K. pneumoniae in southwest Hun-
gary was isolated in the Clinical Centre University of Pecs in
November 2009. Since then, further carbapenemase-producing
isolates have been identified from various departments of the
Clinical Centre. The aim of our study was to identify the
carbapenemase gene and to assess the clonality.
During the study period (29 November 2009 to 31 July
2011), of the 3133 K. pneumoniae clinical isolates (originating
from 1654 patients) identified in the Diagnostic Bacteriological
Laboratory Clinical Centre University of Pecs, 493 (originating
from 198 patients and 15 departments) were supposed to
produce carbapenemase according to screening with disc
diffusion and modified Hodge-test [7]. Of these, 102 were
selected for further investigation. The selection was performed
so as to represent the study period, regarding time of collection
and departments. Only one isolate per patient was included.
Pulsed-field gel electrophoresis was performed as described
previously [8]. Multilocus sequence typing was performed for
three isolates selected according to pulsed-field gel electro-
phoresis subclusters [8]. Confirmation of carbapenemase
production was performed using a phenotypic inhibition assay
with commercially available diagnostic discs (KPC + MBL
Confirmation ID Kit; Rosco, Taastrup, Denmark). The pres-
ence of different b-lactamase genes (blaSHV, blaTEM, blaCTX-M,
blaKPC, blaVIM, blaIMP, blaOXA-48, blaNDM, blaDHA, blaCMY)
was sought by PCR [9–14]. Digestion of blaSHV with NheI was
carried out to identify Gly238?Ser mutation associated with
hydrolysis of third-generation cephalosporins [15]. Sequencing
of blaSHV, blaTEM and blaCTX-M was performed for three
isolates [8]. PCR mapping of integrons was conducted on ten
isolates using primers described previously and sequencing was
performed for one isolate [4]. The MICs of ertapenem,
imipenem and meropenem were measured with gradient test
strips (Liofilchem, Roseto degli Abruzzi, Italy) and the results
were interpreted according to EUCAST guidelines (The
European Committee on Antimicrobial Susceptibility Testing.
Breakpoint tables for interpretation of MICs and zone diam-
eters. Version 3.1, 2013. http://www.eucast.org).
As revealed by pulsed-field gel electrophoresis all but one
isolate belonged to the formerly characterized
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CTX-M-15-producing Hungarian Epidemic Clone (HEC). It
was confirmed with multilocus sequence typing to belong to
ST15. The presence of blaSHV, blaTEM, blaCTX-M and blaVIM
were shown by PCR in 102, 102, 100 and 101 isolates
respectively. All isolates were negative for the Gly238?Ser
mutation of blaSHV. The genes were identified as blaSHV-28,
blaTEM-1, blaCTX-M-15 and blaVIM-4. The presence of a class 1
integron carrying aac(6’)-Ib in the first gene cassette and
blaVIM-4 in the second gene cassette was shown. The integron
was designated as In238b according to the Integrall database
(integrall.bio.ua.pt). The only VIM-negative isolate belonged to
HEC and harboured blaSHV, blaTEM and blaCTX-M genes.
The results of susceptibility testing and phenotypic inhibition
assay for the 101 VIM-positive K. pneumoniae isolates are
summarized in Tables 1 and 2.
This study has shown that the emergence of carbapenem-
ase-producing K. pneumoniae isolates in the Clinical Centre
University of Pecs can be explained by the recent acquisition
and expansion of the blaVIM-4 gene in the nationally dissem-
inated CTX-M-15-producing K. pneumoniae HEC/ST15. To
our knowledge, this is the first description of the blaVIM-4
gene in this international K. pneumoniae clone. The ciproflox-
acin-resistant, CTX-M-15-producing ST15 was first described
in Hungary in 2003. Since then it has become one of the
dominant ESBL-producing K. pneumoniae clones not only in
Hungary but also in several European and Asian countries
[8,16–18]. In238b carrying blaVIM-4 has circulated in Hungary
since 2002, as indicated by continuous isolation in different
species (P. aeruginosa 2002, A. hydrophila 2005, K. pneumoniae
2009, K. oxytoca 2009) [3–5]. Regarding our institution, In238b
was reported earlier in P. aeruginosa and when it was acquired
by HEC/ST15 a remarkable expansion of blaVIM-4 was
observed [19]. Of the 1654 patients from whom K. pneumo-
niae was isolated, 101 (6.1%) were proven to have VIM-pro-
ducing isolates. The resistance conferred by VIM was of low
level. For the majority of the isolates the MIC values of
imipenem and meropenem were near the susceptibility clinical
breakpoint. The low level of resistance hindered detection by
phenotypic inhibition assay, as indicated by the smaller
difference between inhibition zones of meropenem and
meropenem + dipicolinic acid at lower meropenem MIC. This
explains why 51.0% of isolates were not positive for metal-
lo-b-lactamase production in this assay despite production of
VIM being demonstrated by the modified Hodge-test. Con-
sidering the low level of resistance conferred by VIM, the
usage of a modified Hodge-test and the meropenem epidemi-
ological cut-off value proposed by EUCAST (The European
Committee on Antimicrobial Susceptibility Testing. Frequently
Asked Questions. updated 2012-02-12. www.eucast.org) to
screen for carbapenemase production and simultaneous
testing of susceptibility to the three carbapenem derivatives
could be beneficial in the detection of carbapenemase
production in K. pneumoniae. The emergence of VIM-4 metal-
lo-b-lactamase in the predominant ESBL-producing ST15
K. pneumoniae clone is of great concern. It indicates the ability
of this clone to successively adapt to antibiotic pressure. This
fact emphasizes the importance of rational antibiotic usage,
rigorous hospital hygiene measures and the need for devel-
oping newer compounds.
TABLE 1. MIC values and susceptibility of VIM-positive
Klebsiella pneumoniae isolates (n = 101) to different antibiot-
ics according to EUCAST breakpoints (version 3.1
2013-02-11)
Ertapenem Imipenem Meropenem
Range (mg/L) 0.5–32 0.25–32 0.12–32
MIC50 (mg/L) 4 2 1
MIC90 (mg/L) 32 32 2
Susceptible 7 (6.9%) 57 (56.4%) 91 (90.1%)
Intermediate 10 (9.9%) 18 (17.8%) 8 (7.9%)
Resistant 84 (83.2%) 26 (25.7%) 2 (2.0%)
Above ECOFF 101 (100%) 61 (60.4%) 95 (94.1%)
ECOFF, epidemiological cut-off value; MIC50, minimum inhibitory concentration
required to inhibit 50% of isolates; MIC90, minimum inhibitory concentration
required to inhibit 90% of isolates.
TABLE 2. Proportions of metallo-b-lactamase positivity in the phenotypic inhibition assay and mean differences between
inhibition zones of meropenem and meropenem + inhibitor in relation to meropenem MIC for VIM-positive Klebsiella
pneumoniae isolates (n = 101)
Meropenem
n
Boronic acid Dipicolinic acid Cloxacillin MBL
MIC (mg/L) Mean (mm) SD Mean (mm) SD Mean (mm) SD positive (%)
0.12 6 0.8 1.169 2.2 0.983 0.0 0.693 0.0
0.25 21 0.0 1.284 2.8 1.209 0.6 1.284 14.3
0.5 21 0.4 1.284 4.6 1.028 1.1 0.944 52.4
1 30 0.6 1.382 4.8 1.315 1.5 1.042 63.3
2 13 0.4 0.870 4.9 1.256 1.2 1.235 69.2
4 8 0.3 1.753 4.9 0.991 1.0 1.512 75.0
32 2 0.5 0.707 6.0 1.414 0.0 0.000 100.0
all 101 0.3 1.300 4.2 1.567 1.0 1.177 49.0
MBL, metallo-b-lactamase; SD, standard deviation.
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